Levofloxacin hemihydrate
Based on 41 publication(s) in Google Scholar
Levofloxacin hydrate (Levofloxacin hemihydrate) is an orally active broad-spectrum antibacterial agent with antioxidant and antibacterial activities. Levofloxacin hydrate upregulates TC synthesis-related genes and transport-related genes, reduces plasma PCSK9, inhibits GABAA receptors and mitochondrial complexes I/III, scavenges hydroxyl radicals and neutrophil-derived ROS, and inhibits NO metabolites and interferon-γ. Levofloxacin hydrate improves survival, alleviates lung injury, and reduces oxidative and inflammatory markers in influenza virus-infected mice. Levofloxacin hydrate inhibits lung cancer proliferation and xenograft tumor growth, and induces apoptosis and oxidative stress. Levofloxacin hydrate can be used in research on bacterial infection, influenza virus infection, atherosclerosis, and lung cancer.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : 99.98%
- CAS 番号: 138199-71-0
- 分子式: C18H21FN3O4.5
- 分子量:370.38
-
保管条件:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- プロトコル
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
-
HY-B0272
RifampicinAntivirus Agent -
HY-A0276
Gentamicin sulfateAminoglycoside Antibiotic -
HY-17508
ClarithromycinAntimicrobial Agent -
HY-14539
ClozapineAntipsychotic Agent -
HY-14879A
Avibactam sodiumBeta-lactamase Inhibitor -
HY-B0593
CeftazidimeAntibiotic -
HY-14541
Olanzapine5-HT2/D1/D2 Antagonist -
HY-66011A
MoxifloxacinAntibacterial Agent -
HY-Y0320
Dimethyl sulfoxide, meets analytical specification of Ch.P.Aprotic Solvent -
HY-13956
PioglitazonePPARγ Agonist -
HY-17506
Azithromycin -
HY-B0239
ChloramphenicolHIF-1α Inhibitor
MedChemExpress（MCE）の使用を引用している文献 Levofloxacin hydrate
More- Signal Transduct Target Ther. 2025 Dec 15;10(1):406. [Abstract]
- Nat Commun. 2025 May 10;16(1):4366. [Abstract]
- Nat Commun. 2022 Mar 2;13(1):1116. [Abstract]
- Acta Pharm Sin B. 2025 Dec;15(12):6382-6398. [Abstract]
- Sci Adv. 2026 Jun 12;12(24):eaed2731. [Abstract]
- Chem Eng J. 2026 Feb 12.
- J Exp Med. 2026 Mar 2;223(3):e20241287. [Abstract]
- EBioMedicine. 2025 Jul:117:105776. [Abstract]
- Food Res Int. 2026 Aug 31:238:119421. [Abstract]
- Clin Chem. 2019 Dec;65(12):1522-1531. [Abstract]
- Emerg Microbes Infect. 2024 Dec;13(1):2321981. [Abstract]
- Virulence. 2026 Dec 31;17(1):2646808. [Abstract]
- Commun Biol. 2025 Oct 6;8(1):1425. [Abstract]
- Results Chem. 2024 Oct.
- Cell Rep Methods. 2023 Oct 23;3(10):100599. [Abstract]
- Antibiotics (Basel). 2022 Feb 1;11(2):192. [Abstract]
- Int J Antimicrob Agents. 2025 Oct;66(4):107551. [Abstract]
- PLoS Pathog. 2026 Jan 26;22(1):e1013903. [Abstract]
- Toxics. 2025 Feb 5;13(2):122. [Abstract]
- iScience. 2026 Aug 28;29(9):117291.
- ACS Infect Dis. 2024 Apr 12;10(4):1327-1338. [Abstract]
- Antimicrob Agents Chemother. 2021 Feb 17;65(3):e01921-20. [Abstract]
- Microbiol Spectr. 2025 Oct 15:e0122125. [Abstract]
- Microbiol Spectr. 2025 Jul;13(7):e0307424. [Abstract]
- AMB Express. 2024 Dec 24;14(1):141. [Abstract]
- J Med Virol. 2025 Oct;97(10):e70655. [Abstract]
- Water. 2025 Jun 6.
- Infect Drug Resist. 2026 May 8;19.
- Eur J Clin Microbiol Infect Dis. 2025 Sep 29. [Abstract]
- PLoS One. 2026 Jul 8;21(7):e0352997.
- Infect Genet Evol. 2025 Sep:133:105780. [Abstract]
- PLoS One. 2024 Apr 18;19(4):e0298577. [Abstract]
- Future Microbiol. 2025 Oct 13:1-10. [Abstract]
- Chin J Traumatol. 2024 Sep;27(5):295-304. [Abstract]
- Diagn Microbiol Infect Dis. 2026 Nov;116(3):117584.
- Diagn Microbiol Infect Dis. 2026 Feb;114(2):117181. [Abstract]
- Res Sq. 2026 Mar 9.
- SSRN. 2025 Oct 14.
- Res Sq. 2025 Aug 05.
- bioRxiv. 2025 January 19.
- bioRxiv. 2024 May 10.
Customer Validation & Images
-
Microbiological Assay
-
Microbiological Assay
-
Cell Proliferation/Viability Assay
-
Microbiological Assay
-
Microbiological Assay
Topoisomerase アイソフォーム固有の製品をすべて表示
More
生物活性
製品説明
体外実験
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
体内実験
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
- Research Protocol for Infectious Diseases
- Annexin V plus membrane-impermeant dye apoptosis staining
- ROS/oxidative-stress fluorescent staining
- Patient-Derived Orthotopic Xenograft (PDOX)
- Research Protocol for Cardiovascular Diseases
- Cell Viability Determination by MTT Colorimetric Assay
- Phagocytosis Functional Assay
- Detection of Apoptosis
- TUNEL staining for apoptotic DNA fragmentation
- Patient-Derived Xenograft (PDX)
- Apoptosis Solutions
- Splenic/Portal-Vein Liver Metastasis Xenograft
- Inhalation Toxicity Study
- Subcutaneous Cell-Line-Derived Xenograft
- Orthotopic Cell-Line Xenograft
- Intraperitoneal/Peritoneal Dissemination Xenograft
化学情報
-
CAS 番号 138199-71-0
-
性状 Solid
-
分子量 370.38
-
分子式 C18H21FN3O4.5
-
Color White to off-white
-
SMILES
O=C(C(C1=O)=CN2[C@@H](C)COC3=C(N4CCN(C)CC4)C(F)=CC1=C23)O.[0.5H2O]
-
別名
Levofloxacin hydrate; レボオフロキサシン0.5水和物
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (41)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
Selective depletion of tumor-associated SAMHD1 enhances chemotherapeutic efficacy and antitumor immune responses. [Abstract]2025 Dec 15;10(1):406. PMID: 41392286 -
Nat Commun
Phenotypic drug susceptibility testing for Mycobacterium tuberculosis variant bovis BCG in 12 hours. [Abstract]2025 May 10;16(1):4366. PMID: 40348759
Levofloxacin hydrate purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 May 10;16(1):4366. [Abstract]
M. bovis BCG Russia WT in LFX (0-25 h) 1 mg/L.
Levofloxacin hydrate purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 May 10;16(1):4366. [Abstract]
M. bovisBCG Russia FQR in LFX (0-25 h) 1 mg/L.
-
Nat Commun
Antimicrobial resistance and population genomics of multidrug-resistant Escherichia coli in pig farms in mainland China. [Abstract]2022 Mar 2;13(1):1116. PMID: 35236849 -
Acta Pharm Sin B
2025 Dec;15(12):6382-6398. PMID: 41477334
Levofloxacin hydrate purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2025 Dec;15(12):6382-6398. [Abstract]
Levofloxacin exhibited toxicity at 25 × Cmax, which resulted in a 65% reduction in organoid cell viability.
-
Sci Adv
Quantitative prediction of siRNA complexation by ionizable drugs enables their codelivery in nanoparticles. [Abstract]2026 Jun 12;12(24):eaed2731. PMID: 42284421 -
-
J Exp Med
2026 Mar 2;223(3):e20241287. PMID: 41400657 -
EBioMedicine
Diverse impacts of different rpoB mutations on the anti-tuberculosis efficacy of capreomycin. [Abstract]2025 Jul:117:105776. PMID: 40449326
Levofloxacin hydrate purchased from MedChemExpress. Usage Cited in: EBioMedicine. 2025 Jul:117:105776. [Abstract]
Killing curves of different Ms rpoB mutants after exposure to LFX (0-48 h) at 1 μg/mL (5 × MIC) in 7H9 medium.
-
Food Res Int
Prevalence, plasmid transmission, and chromosomal integration of blaCTX-M genes in Salmonella isolated from retail chicken and pork meats in China. [Abstract]2026 Aug 31:238:119421. PMID: 42215089 -
Clin Chem
Discovering Cross-Reactivity in Urine Drug Screening Immunoassays through Large-Scale Analysis of Electronic Health Records. [Abstract]2019 Dec;65(12):1522-1531. PMID: 31578215 -
Emerg Microbes Infect
AMXT-1501 targets membrane phospholipids against Gram-positive and -negative multidrug-resistant bacteria. [Abstract]2024 Dec;13(1):2321981. PMID: 38422452 -
Virulence
Antibacterial efficacy and mechanism of the novel antimicrobial peptide lachnospirin-1 against Acinetobacter baumannii. [Abstract]2026 Dec 31;17(1):2646808. PMID: 41838520 -
Commun Biol
The acetyltransferase CysE modulates virulence and drug resistance of Mycobacterium tuberculosis by interfering with oxidative stress responses. [Abstract]2025 Oct 6;8(1):1425. PMID: 41053365 -
-
Cell Rep Methods
RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]2023 Oct 23;3(10):100599. PMID: 37797618 -
Antibiotics (Basel)
Antibacterial Activity of the Novel Drug Gepotidacin against Stenotrophomonas maltophilia-An In Vitro and In Vivo Study. [Abstract]2022 Feb 1;11(2):192. PMID: 35203795
Levofloxacin hydrate purchased from MedChemExpress. Usage Cited in: Antibiotics (Basel). 2022 Feb 1;11(2):192. [Abstract]
Determined minimum inhibitory concentrations (MICs) of Gepotidacin, Levofloxacin, Moxifloxacin, and Co-trimoxazole against S. maltophilia.
-
Int J Antimicrob Agents
Elucidating adaptive compensatory tigecycline resistance mechanisms of RamA, RarA and SoxS in Klebsiella pneumoniae. [Abstract]2025 Oct;66(4):107551. PMID: 40499596 -
PLoS Pathog
Anti-orthopoxvirus drugs inhibit lumpy skin disease virus replication by targeting viral DNA polymerase. [Abstract]2026 Jan 26;22(1):e1013903. PMID: 41587213 -
Toxics
2025 Feb 5;13(2):122. PMID: 39997937 -
-
ACS Infect Dis
Lusutrombopag as a Repurposing Drug in Combination with Aminoglycosides against Vancomycin-Resistant Enterococcus. [Abstract]2024 Apr 12;10(4):1327-1338. PMID: 38567846 -
Antimicrob Agents Chemother
Dihydrotanshinone I Is Effective against Drug-Resistant Helicobacter pylori In Vitro and In Vivo. [Abstract]2021 Feb 17;65(3):e01921-20. PMID: 33318002 -
Microbiol Spectr
Montelukast treats Streptococcus pneumoniae-induced sepsis via antibacterial and anti-inflammatory activities. [Abstract]2025 Oct 15:e0122125. PMID: 41090944 -
Microbiol Spectr
Antimicrobial resistance of rapidly growing mycobacteria isolated from companion animals in Taiwan. [Abstract]2025 Jul;13(7):e0307424. PMID: 40387379 -
AMB Express
Repurposing pinaverium bromide against Staphylococcus and its biofilms with new mechanisms. [Abstract]2024 Dec 24;14(1):141. PMID: 39718732 -
J Med Virol
Drug Repurposing: In Vitro Evaluation of Simeprevir as a Novel Antiviral Drug Against Severe Fever With Thrombocytopenia Syndrome Virus. [Abstract]2025 Oct;97(10):e70655. PMID: 41117261 -
-
-
Eur J Clin Microbiol Infect Dis
Evaluation of EUCAST rapid antimicrobial susceptibility testing (RAST) for carbapenemase-producing Klebsiella pneumoniae with focus on KPC variants. [Abstract]2025 Sep 29. PMID: 41023358 -
-
Infect Genet Evol
Polymyxin B combined with amikacin delays the resistance of Klebsiella pneumoniae to polymyxin B by modulating the expression of NlpE. [Abstract]2025 Sep:133:105780. PMID: 40480594 -
PLoS One
In vitro activity of ceftazidime/avibactam, cefiderocol, meropenem/vaborbactam and imipenem/relebactam against clinical strains of the Stenotrophomonas maltophilia complex. [Abstract]2024 Apr 18;19(4):e0298577. PMID: 38635685 -
Future Microbiol
2025 Oct 13:1-10. PMID: 41082411 -
Chin J Traumatol
The cytochrome P4501A1 (CYP1A1) inhibitor bergamottin enhances host tolerance to multidrug-resistant Vibrio vulnificus infection. [Abstract]2024 Sep;27(5):295-304. PMID: 38981821 -
-
Diagn Microbiol Infect Dis
2026 Feb;114(2):117181. PMID: 41205476 -
-
-
-
-
溶剤 & 溶解度
体外:
DMSO : 50 mg/mL (135.00 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 10 mg/mL (27.00 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
体内:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 5 mg/mL (13.50 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
純度とドキュメンテーション
-
データシート (294 KB)
-
SDS (419 KB)
- English - EN (419 KB)
- Français - FR (419 KB)
- Deutsch - DE (419 KB)
- Norwegian - NO (419 KB)
- Español - ES (419 KB)
- Swedish - SV (419 KB)
- Italian - IT (419 KB)
- Korean - KR (419 KB)
- Portuguese - PT (419 KB)
-
取扱説明書 (2659 KB)
参考文献
[2]. Sheng Q H, et al. Levofloxacin Ameliorates Atherosclerosis By Regulating Lipid Metabolism. 2025.
[3]. Erden BF, et al. Antidepressant, anxiogenic, and antinociceptive properties of levofloxacin in rats and mice. Pharmacology, biochemistry, and behavior. 2001 Mar;68(3):435-41. [Content Brief]
[4]. Song M, et al. Antibiotic drug levofloxacin inhibits proliferation and induces apoptosis of lung cancer cells through inducing mitochondrial dysfunction and oxidative damage. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2016 Dec;84:1137-1143. [Content Brief]
[5]. JI B, et al. In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1995 Jun;39(6):1341-4. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 2.6999 mL | 13.4996 mL | 26.9993 mL | 67.4982 mL |
| 5 mM | 0.5400 mL | 2.6999 mL | 5.3999 mL | 13.4996 mL | |
| 10 mM | 0.2700 mL | 1.3500 mL | 2.6999 mL | 6.7498 mL | |
| 15 mM | 0.1800 mL | 0.9000 mL | 1.8000 mL | 4.4999 mL | |
| 20 mM | 0.1350 mL | 0.6750 mL | 1.3500 mL | 3.3749 mL | |
| 25 mM | 0.1080 mL | 0.5400 mL | 1.0800 mL | 2.6999 mL | |
| DMSO | 30 mM | 0.0900 mL | 0.4500 mL | 0.9000 mL | 2.2499 mL |
| 40 mM | 0.0675 mL | 0.3375 mL | 0.6750 mL | 1.6875 mL | |
| 50 mM | 0.0540 mL | 0.2700 mL | 0.5400 mL | 1.3500 mL | |
| 60 mM | 0.0450 mL | 0.2250 mL | 0.4500 mL | 1.1250 mL | |
| 80 mM | 0.0337 mL | 0.1687 mL | 0.3375 mL | 0.8437 mL | |
| 100 mM | 0.0270 mL | 0.1350 mL | 0.2700 mL | 0.6750 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Levofloxacin hydrate 関連分類
HY-B0330A 関連分類
Powered by Bioz
Keywords
- Levofloxacin
- 138199-71-0
- Levofloxacin hemihydrate
- Bacterial
- Orthopoxvirus
- Topoisomerase
- Reactive Oxygen Species (ROS)
- GABA Receptor
- PCSK9
- Apoptosis
- Gamma-aminobutyric acid Receptor
- γ-Aminobutyric acid Receptor
- Proprotein convertase subtilisin/kexin type 9
- GABA_A receptor
- LDLR
- antibacterial
- hepatic lipid regulator
- influenza virus
- lung cancer
- mitochondrial complex I
- mitochondrial complex III
- reactive oxygen species
- Inhibitor
- inhibitor
- inhibit